技术分析 - 强生股票当前价格为145 58美元 低于20日144 97美元 50日154 24美元和200日154 66美元的移动平均线 显示出明显的看跌趋势 [4] - 强生股票的技术指标MACD为负2 72 相对强弱指数为36 84 进一步确认了看跌的技术格局 [4] - 强生股票出现了死亡交叉 即50日移动平均线低于200日移动平均线 这通常预示着潜在的下跌风险 [3][6] 公司战略 - 强生在皮肤病学领域采取了战略举措 专注于差异化的作用机制 [5] - 2024年强生通过收购加强了皮肤病学管线 重点开发针对特应性皮炎和其他免疫介导疾病的创新疗法 [5] - 强生与Kaken Pharmaceutical签署了KP-723的许可协议 这是一种针对特应性皮炎的有前景的候选药物 计划于2025年启动一期研究 [11] 财务与股息 - 强生拥有充足的流动性 低杠杆率和强劲的自由现金流 即使在技术性看跌的情况下 其股息可持续性仍然稳固 [9] - 强生作为股息贵族 拥有60多年持续派发股息的历史 为投资者提供了安全网 [12] 市场展望 - 尽管死亡交叉可能对强生股票的短期前景造成阴影 但其对增长 创新和可靠股息的承诺凸显了其长期吸引力 [13] - 强生致力于解决湿疹问题并多元化其产品组合 尽管当前股价下跌 但公司远未出局 [14]

Johnson & Johnson (JNJ)  announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD). The licensing deal for Kaken’s STAT6 program includes global rights to its lead candidate, KP-723.How the Licensing Deal for the AD Program Benefits JNJThe licensing deal with Kaken reinforces Johnson & Johnson’s dedication to targeting disease-specific pa ...

Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you can use to make new investments or cover some of your expenses. The best dividend stocks will send you more money each year by increasing their payments. Anybody can gift oneself with a multiyear supply of passive income by purchasing shares of a high-quality dividend-paying company. Three great ones to consider buying are Coca-Cola (KO -0.27%), Johnson & Johnson (JNJ 0.55%), and NextEra Ener ...

The latest trading session saw Johnson & Johnson (JNJ) ending at $145.27, denoting a +0.55% adjustment from its last day's close. This change lagged the S&P 500's 0.73% gain on the day. Meanwhile, the Dow gained 0.16%, and the Nasdaq, a tech-heavy index, added 0.98%.Prior to today's trading, shares of the world's biggest maker of health care products had lost 6.9% over the past month. This has lagged the Medical sector's loss of 3.8% and the S&P 500's gain of 0.34% in that time.The investment community will ...

After massive rallies delivered by the growth part of my portfolio, it became imbalanced as the share of defensive plays decreased in relative terms. Therefore, I am adding Johnson & Johnson (NYSE: JNJ ) stock to my portfolio andAs an investor who started my path five years ago with my own capital, I represent a blend of hands on experience and academic background in corporate finance. Due to my relatively young age I thrive on discovering long-duration growth opportunities and actively seek out opportuniti ...

The most recent trading session ended with Johnson & Johnson (JNJ) standing at $150.47, reflecting a -1.24% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.61% gain on the day. Elsewhere, the Dow gained 0.69%, while the tech-heavy Nasdaq added 1.31%.The the stock of world's biggest maker of health care products has fallen by 3.78% in the past month, lagging the Medical sector's loss of 1.45% and the S&P 500's gain of 5.79%.Investors will be eagerly watching for the perform ...

文章核心观点 - 强生公司(JNJ)宣布提交了两项补充生物制品许可申请(sBLA)，寻求扩大其药物Tremfya在儿科患者中的使用范围，包括治疗6岁及以上儿童的中重度斑块型银屑病(PsO)和5岁及以上儿童的活动性幼年银屑病关节炎(jPsA) [1] - Tremfya是强生免疫学药物组合中的重要药物，也是推动公司收入增长的关键因素，2024年前九个月的销售额达到27亿美元，同比增长21.6% [4] - 尽管儿科适应症的批准将有助于销售增长，但Tremfya在炎症性肠病(IBD)领域的批准，特别是溃疡性结肠炎(UC)和克罗恩病(CD)，是其增长的关键 [5] Tremfya的儿科适应症申请 - 强生提交了两项sBLA，一项是针对6岁及以上儿童的中重度斑块型银屑病(PsO)，另一项是针对5岁及以上儿童的活动性幼年银屑病关节炎(jPsA) [1] - PsO的sBLA基于儿科患者的III期PROTOSTAR研究数据和成人PsO患者的III期VOYAGE 1和2研究的桥接药代动力学(PK)数据 [3] - jPsA的sBLA基于成人PsA研究的PK外推分析(DISCOVER 1和2)以及PROTOSTAR研究的疗效和安全性数据 [3] Tremfya的市场表现和增长潜力 - Tremfya是强生免疫学药物组合中的重要药物，2024年前九个月的销售额达到27亿美元，同比增长21.6%，主要由市场增长和市场份额增加推动 [4] - 强生预计Tremfya在IBD适应症批准后将成为50亿美元的产品 [7] Tremfya在炎症性肠病(IBD)领域的进展 - Tremfya已于2024年9月获得FDA批准用于中重度活动性UC，并在欧盟接受UC的审查 [6] - Tremfya还在美国和欧盟接受另一种IBD条件，克罗恩病(CD)的审查 [6] 炎症性肠病(IBD)市场的竞争环境 - 近年来，由于遗传因素、环境因素和生活方式的改变，胃肠道疾病如UC和CD的患病率激增 [8] - 免疫系统异常、更高的诊断率、早期诊断的重视以及发达国家的有利报销政策正在推动IBD治疗的需求 [8] - 多家大型制药公司正在开发具有新颖作用机制的新药，以帮助UC和CD患者实现长期临床缓解，包括艾伯维(ABBV)、礼来(LLY)、辉瑞、诺华、默克(MRK)、赛诺菲、吉利德和安进 [9] - 艾伯维预计其关键免疫学药物Skyrizi和Rinvoq在IBD适应症中的销售额将在2024年翻倍，并通过收购小型生物技术公司如Landos Biopharma和Celsius Therapeutics来增强其IBD管线 [10] - 礼来的新药Omvoh于2023年在美国、欧洲和日本获得UC批准，并于2024年为CD提交了监管申请，同时还收购了小型生物技术公司Morphic Therapeutics，其主要候选药物MORF-057处于UC和CD的中期开发阶段 [11] - 默克于2023年收购了小型生物技术公司Prometheus Biosciences，增加了tisokibart/MK-7240到其管线，该药物是一种新颖的TL1A抑制剂，正在III期开发用于UC [12] - 罗氏于2023年收购了Telavant，包括Roivant的TL1A定向抗体RVT-3101的权利，用于治疗IBD条件 [12] - 赛诺菲于2023年10月获得了Teva Pharmaceutical的IBD候选药物TEV'574的联合开发和商业化权利，该药物是一种抗-TL1A疗法，正在IIb期研究中评估用于UC和CD [13]

Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis  SPRING HOUSE, Pa., Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis (PsO) and children 5 years of age and older wi ...

BRIDGEWATER, N.J. and BENGALURU, India, Dec. 2, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA) has approved YESINTEK™ (Ustekinumab-kfce), a biosimilar to the reference product, Stelara® (Ustekinumab). YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic a ...

文章核心观点 - 将最大的股息投资组合比例分配给强生公司（Johnson & Johnson）可以有效降低投资组合的波动性，作为战略防御措施 [1] 投资策略 - 专注于构建旨在通过股息产生额外收入的投资组合，重点关注具有显著竞争优势和强大财务状况的公司，以提供有吸引力的股息收益率和股息增长 [1] - 通过结合高股息收益率和股息增长公司，逐步减少对整个股市波动的依赖 [1] - 建议在投资组合中纳入低贝塔系数的公司，以进一步降低整体风险水平 [1] 投资组合构建 - 投资组合通常由ETF和个别公司混合组成，强调广泛的多元化和风险降低 [1] - 投资组合的构建过程经过精心策划，优先考虑总回报，包括资本收益和股息，而不仅仅是孤立地关注股息 [1] 多元化策略 - 帮助投资者在各个行业和部门实现多元化投资组合，以最小化投资组合波动性和降低风险 [1]